Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 8/2003

01-08-2003 | Article

Pancreatic NOD beta cells express MHC class II protein and the frequency of I-Ag7 mRNA-expressing beta cells strongly increases during progression to autoimmune diabetes

Authors: Dr. U. Walter, T. Toepfer, K. E. J. Dittmar, K. Kretschmer, J. Lauber, S. Weiss, G. Servos, O. Lechner, W. A. Scherbaum, S. R. Bornstein, H. von Boehmer, J. Buer

Published in: Diabetologia | Issue 8/2003

Login to get access

Abstract

Aims/hypothesis

In the NOD mouse model, attempts to show MHC class II expression by pancreatic beta cells were unsuccessful so far. We readdressed this question by analysing I-Ag7 expression in single pancreatic beta cells.

Methods

Single-cell multiplex RT PCR and single-cell immunofluorescence were used to study MHC class II expression in NOD and NOD/SCID beta cells.

Results

Pancreatic beta cells from NOD mice express the I-Ag7 protein as well as the corresponding mRNA. The frequency of MHC class II mRNA-expressing beta cells is drastically increased during the progression to overt diabetes. MHC class II protein is accumulated intracellularly, and invariant chain is co-expressed. Beta cells from 9- to 10-week-old NOD/SCID mice express MHC class II at the same low frequency as beta cells from 3-week-old NOD mice.

Conclusion/interpretation

NOD beta cells express I-Ag7 and could be a direct target of autoreactive CD4+ T cells. This MHC class II expression is triggered by infiltrating lymphocytes.
Literature
1.
Andre I, Gonzalez A, Wang B, Katz J, Benoist C, Mathis D (1996) Checkpoints in the progression of autoimmune disease: lessons from diabetes models. Proc Natl Acad Sci USA 93:2260–2263CrossRefPubMed
2.
Matsumoto M, Yagi H, Kunimoto K, Kawaguchi J, Makino S, Harada M (1993) Transfer of autoimmune diabetes from diabetic NOD mice to NOD athymic nude mice: the roles of T cell subsets in the pathogenesis. Cell Immunol 148:189–197CrossRefPubMed
3.
Bendelac A, Carnaud C, Boitard C, Bach JF (1987) Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt-2+ T cells. J Exp Med 166:823–832PubMed
4.
Edouard P, Hiserodt JC, Plamondon C, Poussier P (1993) CD8+ T-cells are required for adoptive transfer of the BB rat diabetic syndrome. Diabetes 42:390–397PubMed
5.
Miller BJ, Appel MC, O'Neil JJ, Wicker LS (1988) Both the Lyt-2+ and L3T4+ T cell subsets are required for the transfer of diabetes in nonobese diabetic mice. J Immunol 140:52–58PubMed
6.
Yamada K, Miyajima E, Nonaka K (1990) Inhibition of cytokine-induced MHC class II but not class I molecule expression on mouse islet cells by niacinamide and 3-aminobenzamide. Diabetes 39:1125–1130PubMed
7.
Pujol-Borrell R, Todd I, Doshi M, Bottazzo GF, Sutton R, Gray D, Adolf GR, Feldmann M (1987) HLA class II induction in human islet cells by interferon-gamma plus tumour necrosis factor or lymphotoxin. Nature 326:304–306CrossRefPubMed
8.
Campbell IL, Oxbrow L, Koulmanda M, Harrison LC (1988) IFN-gamma induces islet cell MHC antigens and enhances autoimmune, streptozotocin-induced diabetes in the mouse. J Immunol 140:1111–1116PubMed
9.
Bottazzo GF, Dean BM, McNally JM, MacKay EH, Swift PG, Gamble DR (1985) In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med 313:353–360
10.
Dean BM, Walker R, Bone AJ, Baird JD, Cooke A (1985) Pre-diabetes in the spontaneously diabetic BB/E rat: lymphocyte subpopulations in the pancreatic infiltrate and expression of rat MHC class II molecules in endocrine cells. Diabetologia 28:464–466PubMed
11.
Campbell IL, Oxbrow L, West J, Harrison LC (1988) Regulation of MHC protein expression in pancreatic beta-cells by interferon-gamma and tumor necrosis factor-alpha. Mol Endocrinol 2:101–107PubMed
12.
Walker R, Cooke A, Bone AJ, Dean BM, van der MP, Baird JD (1986) Induction of class II MHC antigens in vitro on pancreatic B cells isolated from BB/E rats. Diabetologia 29:749–751PubMed
13.
Foulis AK, Farquharson MA (1986) Aberrant expression of HLA-DR antigens by insulin-containing beta-cells in recent-onset type I diabetes mellitus. Diabetes 35:1215–1224PubMed
14.
McInerney MF, Rath S, Janeway CA, Jr. (1991) Exclusive expression of MHC class II proteins on CD45+ cells in pancreatic islets of NOD mice. Diabetes 40:648–651PubMed
15.
Mathis D, Vence L, Benoist C (2001) beta-cell death during progression to diabetes. Nature 414:792–798CrossRefPubMed
16.
Chaturvedi P, Agrawal B, Zechel M, Lee-Chan E, Singh B (2000) A self MHC class II beta-chain peptide prevents diabetes in nonobese diabetic mice. J Immunol 164:6610–6620PubMed
17.
Boitard C, Bendelac A, Richard MF, Carnaud C, Bach JF (1988) Prevention of diabetes in nonobese diabetic mice by anti-I-A monoclonal antibodies: transfer of protection by splenic T cells. Proc Natl Acad Sci USA 85:9719–9723PubMed
18.
Peterson JD, Haskins K (1996) Transfer of diabetes in the NOD-scid mouse by CD4 T-cell clones. Differential requirement for CD8 T-cells. Diabetes 45:328–336PubMed
19.
Zekzer D, Wong FS, Ayalon O, Millet I, Altieri M, Shintani S, Solimena M, Sherwin RS (1998) GAD-reactive CD4+ Th1 cells induce diabetes in NOD/SCID mice. J Clin Invest 101:68–73PubMed
20.
Kurrer MO, Pakala SV, Hanson HL, Katz JD (1997) Beta cell apoptosis in T cell-mediated autoimmune diabetes. Proc Natl Acad Sci USA 94:213–218PubMed
21.
O'Reilly LA, Hutchings PR, Crocker PR, Simpson E, Lund T, Kioussis D, Takei F, Baird J, Cooke A (1991) Characterization of pancreatic islet cell infiltrates in NOD mice: effect of cell transfer and transgene expression. Eur J Immunol 21:1171–1180PubMed
22.
Walter U, Franzke A, Sarukhan A, Zober C, Boehmer Hv, Buer J, Lechner O (2000) Monitoring gene expression of TNFR family members by beta-cells during development of autoimmune diabetes. Eur J Immunol 30:1224–1232CrossRefPubMed
23.
Pilstrom B, Bjork L, Bohme J (1995) Demonstration of a TH1 cytokine profile in the late phase of NOD insulitis. Cytokine 7:806–814CrossRefPubMed
24.
Rosmalen JG, Homo-Delarche F, Durant S, Kap M, Leenen PJ, Drexhage HA (2000) Islet abnormalities associated with an early influx of dendritic cells and macrophages in NOD and NODscid mice. Lab Invest 80:769–777PubMed
25.
Tian J, Atkinson MA, Clare-Salzler M, Herschenfeld A, Forsthuber T, Lehmann PV, Kaufman DL (1996) Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 183:1561–1567PubMed
26.
Polanski M, Melican NS, Zhang J, Weiner HL (1997) Oral administration of the immunodominant B-chain of insulin reduces diabetes in a co-transfer model of diabetes in the NOD mouse and is associated with a switch from Th1 to Th2 cytokines. J Autoimmun 10:339–346CrossRefPubMed
27.
Viville S, Neefjes J, Lotteau V, Dierich A, Lemeur M, Ploegh H, Benoist C, Mathis D (1993) Mice lacking the MHC class II-associated invariant chain. Cell 72:635–648PubMed
28.
Pierre P, Turley SJ, Gatti E, Hull M, Meltzer J, Mirza A, Inaba K, Steinmann RM, Mellman I (1997) Developmental regulation of MHC class II transport in mouse dendritic cells. Nature 388:787–792PubMed
29.
Pierre P, Mellman I (1998) Developmental regulation of invariant chain proteolysis controls MHC class II trafficking in mouse dendritic cells. Cell 93:1135–1145PubMed
30.
Hamaguchi K, Gaskins HR, Leiter EH (1991) NIT-1, a pancreatic beta-cell line established from a transgenic NOD/Lt mouse. Diabetes 40:842–849PubMed
31.
Kim KA, Kim S, Chang I, Kim GS, Min YK, Lee MK, Kim KW, Lee MS (2002) IFN gamma/TNF alpha synergism in MHC class II induction: effect of nicotinamide on MHC class II expression but not on islet-cell apoptosis. Diabetologia 45:385–393CrossRef
32.
Tisch R, Yang XD, Singer SM, Liblau RS, Fugger L, McDevitt HO (1993) Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice [see comments]. Nature 366:72–75PubMed
33.
Kaufman DL, Clare-Salzler M, Tian J, Forsthuber T, Ting GS, Robinson P, Atkinson MA, Sercarz EE, Tobin AJ, Lehmann PV (1993) Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes [see comments]. Nature 366:69–72PubMed
34.
Tian J, Lehmann PV, Kaufman DL (1997) Determinant spreading of T helper cell 2 (Th2) responses to pancreatic islet autoantigens. J Exp Med 186:2039–2043CrossRefPubMed
35.
Hoglund P, Mintern J, Waltzinger C, Heath W, Benoist C, Mathis D (1999) Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes. J Exp Med 189:331–339PubMed
36.
Kurts C, Kosaka H, Carbone FR, Miller JFAP, Heath WR (1997) Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8+ T cell. J Exp Med 185:239CrossRefPubMed
37.
Forster I, Lieberam I (1996) Peripheral tolerance of CD4+ T cells following local activation in adolescent mice. Eur J Immunol 26:3194PubMed
38.
Morgan DJ, Kreuwel HTC, Sherman LA (1999) Antigen concentration and precursor frequency determine the rate of CD8+ T cell tolerance to peripherally expressed antigens. J Immunol 163:723PubMed
39.
Morgan DJ, Kurts C, Kreuwel HTC, Holst K, Heath WR, Sherman LA (1999) Ontogeny of tolerance to peripherally-expressed antigens. Proc Natl Acad Sci USA 30:3845
40.
Lo D, Reilly CR, Scott B, Liblau R, McDevitt HO, Burkly LC (1993) Antigen-presenting cells in adoptively transferred and spontaneous autoimmune diabetes. Eur J Immunol 23:1693–1698PubMed
41.
LaFace DM, Peck AB (1989) Reciprocal allogeneic bone marrow transplantation between NOD mice and diabetes-nonsusceptible mice associated with transfer and prevention of autoimmune diabetes. Diabetes 38:894–901PubMed
42.
Sarukhan A, Lechner O, von Boehmer H (1999) Autoimmune insulitis and diabetes in the absence of antigen-specific contact between T cells and islet beta-cells. Eur J Immunol 29:3410–3416CrossRefPubMed
43.
Rees MA, Rosenberg AS, Munitz TI, Singer A (1990) In vivo induction of antigen-specific transplantation tolerance to Qa1a by exposure to alloantigen in the absence of T-cell help. Proc Natl Acad Sci USA 87:2765–2769PubMed
44.
Guerder S, Matzinger P (1992) A fail-safe mechanism for maintaining self-tolerance. J Exp Med 176:553–564PubMed
45.
Kirberg J, Bruno L, Boehmer H von (1993) CD4+8− help prevents rapid deletion of CD8+ cells after a transient response to antigen. Eur J Immunol 23:1963–1967PubMed
46.
Kurts C, Carbone FR, Barnden M, Blanas E, Allison J, Heath WR, Miller JF (1997) CD4+ T cell help impairs CD8+ T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity. J Exp Med 186:2057–2062PubMed
47.
Kurts C, Miller JF, Subramaniam RM, Carbone FR, Heath WR (1998) Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J Exp Med 188:409–414PubMed
Metadata
Title
Pancreatic NOD beta cells express MHC class II protein and the frequency of I-Ag7 mRNA-expressing beta cells strongly increases during progression to autoimmune diabetes
Authors
Dr. U. Walter
T. Toepfer
K. E. J. Dittmar
K. Kretschmer
J. Lauber
S. Weiss
G. Servos
O. Lechner
W. A. Scherbaum
S. R. Bornstein
H. von Boehmer
J. Buer
Publication date
01-08-2003
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 8/2003
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-003-1164-y

Other articles of this Issue 8/2003

Diabetologia 8/2003 Go to the issue

Article

Hypoglycaemia induces decreased islet blood perfusion mediated by the central nervous system in normal and Type 2 diabetic GK rats

Article

LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats

Article

Alteration in haemodynamics and pathological changes in the cardiovascular system during the development of Type 2 diabetes mellitus in OLETF rats

Article

Erk 1,2 phosphorylates p27Kip1: Functional evidence for a role in high glucose-induced hypertrophy of mesangial cells

Article

The influence of the ACE (I/D) polymorphism on systemic and renal vascular responses to angiotensins in normotensive, normoalbuminuric Type 1 diabetes mellitus

Article

Meta-analysis of the effect of structured exercise training on cardiorespiratory fitness in Type 2 diabetes mellitus
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits